retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Retatrutide Phase 3 Updates: Significant

Studied as a stronger alternative to semaglutide

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al

Home Metabolic Retatrutide (30mg) Metabolic Research Peptide GLP-1 / GIP / Glucagon triple-receptor agonist Research-grade, Australia In stock dispatched Australia-wide View & buy on store Retatrutide (development code LY3437943) is a synthetic triple-agonist peptide that acts on three metabolic receptor targets at once: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

Kuzio, Dryburgh, Malloy, Brown

Tip 2 : Once you print it, go through it and see what you like/dont like

Participants over 55 responded nearly as well as younger cohorts, suggesting the mechanism works effectively regardless of age-related metabolic changes